That was a central message of the fourth Swiss-Hungarian Healthcare Forum, held at Semmelweis University in Budapest.

Organized by Swisscham Hungary and the Swiss Embassy, together with professional partners Novartis, Roche and Sandoz, the forum brought together government, healthcare, academic and pharmaceutical industry representatives to discuss a more resilient, innovative and sustainable healthcare system.

The event coincided with the 80th anniversary of the resumption of Swiss-Hungarian diplomatic relations and Swisscham Hungary’s 30th anniversary.

In his opening address, Swiss Ambassador Alexander Renggli emphasized the importance of international cooperation in addressing increasingly complex healthcare challenges.

“Healthcare’s most complex challenges cannot be addressed in isolation. Genuine progress requires international expertise, the application of local experience and close cooperation among participants in the healthcare ecosystem. The unprecedented collaboration between Swiss and Hungarian partners advances healthcare innovation and contributes to strengthening Europe’s competitiveness and economic growth,” Renggli said.

Connecting Prevention, Treatment and Innovation

The discussions focused on three interconnected priorities: reducing the burden of cardiovascular disease, strengthening healthcare institutions’ role in scientific and biotechnology innovation, and turning development funding into lasting improvements across the system.

Participants included parliamentary Health Committee Chair Diána Ruzsa; Árpád Tótth, director of the National Directorate General for Hospitals; Zoltán Kaló, director of the National Health Insurance Fund; László Gellér, president of the Hungarian Society of Cardiology; Imre Hild, CEO of the National Innovation Agency; and Roland Python, head of the Swiss Contribution Program Office in Hungary.

The cardiovascular discussion emphasized the connections between prevention, early diagnosis, treatment and long-term care. Participants examined how clinical expertise, health policy, financing, patient advocacy and European initiatives, including the Safe Hearts Plan, could contribute to improvements throughout the patient journey.

A separate panel explored how hospitals and universities could become more active centers of innovation, alongside their roles in treatment and education.

The discussion considered closer cooperation among public institutions, universities, research organizations, startups and industry in life sciences and biotechnology. A recurring argument was that healthcare institutions can generate scientific and economic value while improving care.

Turning Pilot Projects Into Lasting Solutions

Discussions on development and cohesion funding focused on implementation: learning from earlier healthcare projects, directing resources toward the greatest patient and social benefits, and expanding successful pilots into sustainable solutions that can be used nationwide.

Participants emphasized that introducing new technologies and therapies is only part of the challenge. Healthcare systems also need the capacity to identify, assess, adopt and widely apply solutions that demonstrably improve patient pathways, care quality and sustainability.

The conditions discussed included predictable regulation and financing, institutions equipped to participate in research, responsible data management and trust between public and private organizations.

“Hungary has all the assets needed to build a competitive healthcare innovation ecosystem: excellent professionals, strong clinical centers and valuable health data. Our shared goal is to build on these strengths to create meaningful, innovative solutions that serve patients’ interests more quickly, predictably and sustainably,” said Mohamed Tammam, managing director of Novartis Hungária.

Healthcare as an Economic Growth Driver

Peter Ahnesorg, managing director of Roche Hungary, argued that healthcare and life sciences should be viewed as contributors to economic development.

“Hungary stands at the threshold of a historic opportunity: funding flowing into healthcare over the coming years could provide an unprecedented boost to the country’s competitiveness and bring it closer to the key economic and social objectives set for the next two parliamentary terms — including the introduction of the euro. Healthcare and the life sciences sector are not a cost factor but a critical engine of growth for the entire economy,” Ahnesorg said.

“Combining early, accurate diagnostics and precision therapies with stable clinical infrastructure and health data assets can create a sustainable model in which innovation translates into directly measurable patient care outcomes. At Roche, we believe that partnerships between countries, such as cooperation between Hungary and Switzerland, are essential to turning this momentum into tangible benefits for Hungarian patients,” he added.

Max Juerging, Sandoz’s director responsible for transformation and growth in Switzerland, emphasized cooperation and access to affordable medicines.

“Close cooperation among governments, healthcare providers and industry is essential to building more adaptable and sustainable healthcare systems. Hungary has solid foundations on which to build further in this area, and Sandoz remains committed to supporting this development by expanding access to high-quality, affordable medicines,” Juerging said.

Across the discussions, the test of success was whether partnerships and investment would deliver faster patient pathways, better health outcomes, stronger research capabilities and more sustainable care.